Market Overview

Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical Trial Results Soon

In an exclusive Expert Briefing at BioMedReports, Yuichi Iwaki, M.D., Ph.D., the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma, a long-lasting and severe form of asthma episode in which symptoms are unresponsive to initial bronchodilator or corticosteroid therapy.

Some staggering statistics show that AEA episodes account for more than 1.5 million annual emergency room visits in the U.S. alone, and no new options have been introduced in the emergency setting during the past two decades. The lack of treatment options and increasing costs represent an urgent need for innovative approaches.

Posted-In: News FDA

 

Related Articles (MNOV)

Around the Web, We're Loving...

Get Benzinga's Newsletters